All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
28‐Day all‐cause mortalitya · children and adults with sepsis
Corticosteroids probably leads to lower 28‐Day all‐cause mortalitya compared with placebo or usual care (moderate certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
All‐cause mortality (at day 28) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · non‐hospitalised adults with mild COVID‐19
1 finding from 1 review
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Neonatal mortality · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review